ICU幸存者中长期高效价苯二氮䓬类药物的启用:一项全国性队列研究
该回顾性队列研究基于瑞典2010-2017年全部ICU登记数据,筛选237,904例,纳入137,647例ICU存活至少3个月且入院前未使用高效价苯二氮䓬类的患者。出院后5338例(3.9%)成为长期使用者,处方高峰出现在前3个月,并持续至18个月随访期。长期使用与高龄、女性、躯体和精神共病(包括物质滥用)、较长ICU停留、高估计死亡率及既往低效价苯二氮䓬类使用相关。使用者ICU入院后6-18个月死亡风险显著升高(校正HR 1.8,95%CI 1.7-2.0,P<0.001),死因无差异。
要点
- ICU存活至少3个月且入院前未用高效价苯二氮䓬类者中,3.9%(5338/137,647)在出院后成为长期使用者。
- 高效价苯二氮䓬类处方高峰在出院后前3个月,并持续整个18个月随访期。
- 长期使用相关因素包括高龄、女性、躯体和精神共病(含物质滥用)、较长ICU停留、高估计死亡率及既往低效价苯二氮䓬类使用。
- 高效价苯二氮䓬类使用者在ICU入院后6-18个月死亡风险升高(校正HR 1.8,95%CI 1.7-2.0,P<0.001),使用者与非使用者死因无差异。
适用人群与场景
- 瑞典2010-2017年所有登记ICU入住患者中,存活至少3个月且入院前未使用高效价苯二氮䓬类者。
研究设计与关键结果
- 研究类型:回顾性队列研究;筛查237,904例,纳入137,647例ICU存活至少3个月且入院前未使用高效价苯二氮䓬类的患者。
- 主要结果:5338例(3.9%)在ICU出院后成为高效价苯二氮䓬类长期使用者;处方高峰出现在前3个月,并持续整个18个月随访期。
- 长期使用相关因素:高龄、女性、躯体和精神共病(包括物质滥用)、较长ICU停留、高估计死亡率及既往低效价苯二氮䓬类使用。
- 死亡风险:高效价苯二氮䓬类使用者ICU入院后6-18个月死亡风险显著升高,校正HR 1.8(95%CI 1.7-2.0;P<0.001);使用者与非使用者死因无差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,考虑到ICU入住人数众多,预防苯二氮䓬类误用可能改善重症监护后的长期结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Exposure to critical illness and intensive care may lead to long-term psychologic and physical impairments. To what extent ICU survivors become prolonged users of benzodiazepines after exposure to critical care is not fully explored. This study aimed to describe the extent of onset of prolonged high-potency benzodiazepine use among ICU survivors not using these drugs before admission, identify factors associated with this use, and analyze whether such usage is associated with increased mortality.
DESIGN: Retrospective cohort study.
SETTING: Sweden, including all registered ICU admissions between 2010 and 2017.
PATIENTS: ICU patients surviving for at least 3 months, not using high-potency benzodiazepine before admission, were eligible for inclusion.
INTERVENTIONS: Admission to intensive care.
MEASUREMENTS AND MAIN RESULTS: A total of 237,904 patients were screened and 137,647 were included. Of these 5338 (3.9%) became prolonged users of high-potency benzodiazepines after ICU discharge. A peak in high-potency benzodiazepine prescriptions was observed during the first 3 months, followed by sustained usage throughout the follow-up period of 18 months. Prolonged usage was associated with older age, female sex, and a history of both somatic and psychiatric comorbidities, including substance abuse. Additionally, a longer ICU stay, a high estimated mortality rate, and prior consumption of low-potency benzodiazepines were associated with prolonged use. The risk of death between 6 and 18 months post-ICU admission was significantly higher among high-potency benzodiazepine users, with an adjusted hazard ratio of 1.8 (95% CI, 1.7-2.0; p < 0.001). No differences were noted in causes of death between users and nonusers.
CONCLUSIONS: Despite the lack of evidence supporting long-term treatment, prolonged usage of high-potency benzodiazepines 18 months following ICU care was notable and associated with an increased risk of death. Considering the substantial number of ICU admissions, prevention of benzodiazepine misuse may improve long-term outcomes following critical care.
参考来源
- Lindström AC, von Oelreich E, Eriksson J, et al. Onset of Prolonged High-Potency Benzodiazepine Use Among ICU Survivors: A Nationwide Cohort Study. Crit Care Explor. 2024. PMID: 38984149. doi:10.1097/CCE.0000000000001124
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。